ARWR

Arrowhead Pharma

Fundamental data last updated:April 13, 2026

company profile

SECTOR

Healthcare

industry

Biotechnology

Exchange

Nasdaq

County of HQ

United States

Next Earnings Date

05/11/26

Business Summary

AMN Healthcare Services operates as a healthcare workforce solutions provider, connecting medical professionals with hospitals and care facilities that need flexible staffing. The core cash engine comes from placing nurses, physicians, and allied health professionals on temporary or permanent assignments and earning spreads on those placements. Scale matters: a larger network improves fill rates, pricing power, and client retention, which can create switching costs for both providers and clinicians. The moat, while not technological in the traditional sense, is built on relationships, credentialing infrastructure, compliance capabilities, and the ability to efficiently match supply and demand in a highly regulated labor market.

VALUATION

P/E

40.7

Market Cap ($M USD)

$9,121

Forward P/E

-

PEG

-

PRICE TO SALES

8.2

PRICE TO BOOK

16.1

EV / EBITDA

23

5-Year Average P/E

DIVIDEND

Yield

-

Annual Payout

-

Payout Ratio

-

Consecutive Years of Dividend Growth

0

5-Year Dividend Growth Rate

-

Financial Health & Profitability

Earnings Per Share

$1.60

Next Year EPS Growth Estimate

-$4.30

Next Year Revenue Growth Estimate

-29.30%

Return on Equity (ROE)

35.60%

Operating Margin

27.60%

Debt-to-Equity

0.6

Piotroski F-Score

6

Altman Z-Score

5.8

Return on Invested Capital (ROIC)

33.20%%

Current Ratio

3.4

Quick Ratio

Gainseekers Quantitative Analysis

Summary

At a $690M market cap with a Forward P/E of 15.7, AMN is being valued as a stabilization story, not a growth compounder. The absence of a trailing P/E, negative ROE of -15.30%, negative operating margin of -14.90%, and ROIC of -3.20% signal a business currently destroying shareholder capital, yet the Altman Z-Score of 2.4 suggests it is not in immediate distress. The market is pricing in survival and modest normalization rather than expansion, especially with EPS expected at -$2.48 next year despite a current EPS figure of 14.4. This is not a premium-quality operator, but at 0.3x sales and 1.1x book, it is being valued like a damaged cyclical asset rather than a terminal decline.

AI Exposure / Tech Reliance

As a Medical Care Facilities company within Healthcare, AMN operates in a sector increasingly shaped by workforce automation, scheduling algorithms, and AI-driven staffing optimization. AI integration could materially improve cost efficiency and placement accuracy, which is critical given the current -14.90% operating margin. However, healthcare staffing remains human-capital intensive, limiting full automation and keeping execution risk elevated.

The Bull Case

A deep value or GARP investor could argue the 0.3 Price/Sales and 1.1 Price/Book ratios already discount significant operational weakness, creating asymmetric upside if margins normalize. The Piotroski F-Score of 5 indicates financial condition is not collapsing, just middling, while the Altman Z-Score of 2.4 keeps the company out of the distress zone. Institutional ownership at 22.21 suggests some professional capital remains engaged, and a 1.3 TTM yield offers modest carry despite no stated dividend per share. If operating margins recover from -14.90% and ROIC moves from -3.20% back into positive territory, even a steady 15.7 forward multiple could translate into meaningful upside from a depressed base.

The Bear Case

The bear case is blunt: negative ROE of -15.30%, negative ROIC of -3.20%, and a -14.90% operating margin indicate a structurally impaired earnings engine. The company is expected to post EPS of -$2.48 next year, which makes the 15.7 Forward P/E fragile and highly assumption-dependent. A Current Ratio of 0.9 suggests tight liquidity, and while Debt/Equity at 1.20% appears low, weak profitability undermines balance sheet flexibility. With no PEG provided and no evidence of sustainable growth beyond a vague Sales Growth Next Year figure of $1.14, this looks more like a turnaround gamble than a disciplined GARP opportunity.

Market Sentiment & Smart Money

Short Interest %

11.40%

Analyst Consensus

1.69

Average Analyst Price Target

$81.67

Institutional Ownership %

84.50%

1-Year Beta

1.72

Insider Buying % (6 Mo)

3.80%%

Distance to 52-Week High

84.90%%

Distance to 52-Week Low

606.00%%